GENETICS GENERATION ADVANCEMENT CORP. (GGA CORP.)-AI-powered Exosomal miRNA Precision Target Analysis Platform

Category: *Precision Health & Smart Medical

Exhibitor: DEPARTMENT OF SOCIAL WELFARE, TAIPEI CITY GOVERNMENT

Booth No: N402

Characteristic

GGA Corp. independently developed the DeepExoMir platform, leveraging AI deep learning and multimodal feature engineering to focus on regenerative medicine, skin repair, hair regeneration, and immune modulation. The platform analyzes miRNA functions and integrates a biological pathway database to enable key pathway regulation and automated indication recommendations. Using the Exo-W index, it quantifies functional differences across product sources. DeepExoMir offers advantages in cross-species, multi-source, and end-to-end biological pathway interpretation, achieving prediction accuracy above 0.96. Since its launch in 2023, it has supported multiple product validations and market entries. Over the next three years, DeepExoMir will advance cloud-based SaaS and API integration, expand international partnerships, and drive scalable, high-value applications in the exosome industry.